Trastuzumab Biosimilar Litigation update (US): Genentech VS Tanvex Case update

As previously reported (Click here to view previous post), Genentech and Tanvex reached an agreement in January 2022 to end the BPCIA dispute involving Tanvex's biosimilar for Herceptin (Trastuzumab). The court issued an order dismissing all of the case's allegations on Feb 9, 2023. 

Note: The FDA has not yet given its approval to Tanvez's Trastuzumab Biosimilar.